References
- Callen J. Dermatomyositis. Lancet. 2000;355(9197):53–7.
- Marie I, Hachulla E, Chérin P, Dominique S, Hatron P, Hellot M, et al. Interstitial lung disease in polymyositis and dermatomyo-sitis. Arthritis Rheum. 2002;47(6):614–22.
- Ito M, Kaise S, Suzuki S, Kazuta Y, Sato Y, Miyata M, et al. Clinico-laboratory characteristics of patients with dermatomyo-sitis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol. 1999;18(6):462–7.
- Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermato-myositis. J Rheumatol. 2005;32(9):1719–26.
- Gerami P, Schope J, McDonald L, Walling H, Sontheimer R. A systematic review of adult-onset clinically amyopathic der-matomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54(4):597–613.
- Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52(5):1571–6.
- Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Kuwana M. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyo-pathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60(7):2193–200.
- Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a der-matomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010;49(3):433–40.
- Fathi M, Vikgren J, Boijsen M, Tylen U, Joffeldt L, Tornling G, et al. Interstitial lung disease in polymyositis and dermatomyo-sitis: longitudinal evaluation by pulmonary function and radiol-ogy. Arthritis Rheum. 2008;59(5):677–85.
- Gono T, Kawaguchi Y, Hara M, Masuda I, Katsumata Y, Shinozaki M, et al. Increased fenitin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49(7):1354–60.
- Hintze K, Theil E. Cellular regulation and molecular interactions of the fenitins. Cell Mol Life Sci. 2006;63(5):591–600.
- Tristano A. Macrophage activation syndrome: a frequent but under-diagnosed complication associated with rheumatic dis-eases. Med Sci Monit. 2008;14(3):RA27–36.
- Henter J, Horne A, Arid:, M, Egeler R, Filipovich A, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31.
- Takeuchi O, Akira S. MDA5/RIG-I and virus recognition. Curr Opin Immunol. 2008;20(1):17–22.
- Christensen M, Pachman L, Schneiderman R, Patel D, Friedman J. Prevalence of Coxsackie B virus antibodies in patients with juve-nile dermatomyositis. Arthritis Rheum. 1986;29(11):1365–70.
- Ward P, Hunninghake G. Lung inflammation and fibrosis. Am J Respir Crit Care Med. 1998;157(4 Pt 2):S123–9.